Neuralstem, Inc. reported that Eva Feldman, MD, PhD, principal investigator, presented updated Phase I data from its spinal cord-derived human neural stem cell (NSI-566) trial in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) at the neuro diabetes special medical Dr.

read more>>

BioMarin Pharmaceutical Inc. announced that data from its ongoing Phase 1/2 trial for BMN-673 for genetically-defined cancers will be released at the American Society of Clinical Oncology (ASCO) meeting in Chicago on June 3, 2013. At ASCO, the company will present data from 18 gBRCA breast cancer

read more>>

King's College Hospital have launched the first trial of the DCVax® therapy in Europe which is already significantly extending life for patients in a US trialThe brain cancer trial uses the patient's tumour to develop their own personalised vaccineKing's - part of King's Health Partners AHSC -wi

read more>>

Northwest Biotherapeutics (NW Bio), a biotechnology company developing DCVax®-L personalized immune therapies for solid tumor cancers, announced that its Phase III clinical trial with DCVax®-L for brain cancer has been initiated at King's College Hospital in the UKThis is one of the first late-s

read more>>

LEXINGTON, Mass.-- Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to sebelipase alfa for the treatment of Acc

read more>>

ARDSLEY, N.Y.-- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Application No. 8,440,703 (“the ‘703 patent”) entitled “Methods of Using Sustained Release Aminopyridine Compositions.” The ‘703 pat

read more>>

Madrid - Zeltia announces that its subsidiary PharmaMar has commenced a Phase Ib trial with PM01183 in combination with Capecitabine. It is a prospective open escalating dose Phase I trial with PM01183 and Capecitabine in patients with unresectable metastatic breast cancer, pancreatic cancer, an

read more>>

RuiYi Inc. announced that it has entered into an exclusive license and collaborative development agreement with Genor BioPharma for the development of RYI-008 in China. RYI-008 is a novel anti-IL-6 monoclonal antibody with a unique pharmacologic profile that has the potential to define a new "RYI-

read more>>

MultiCell Technologies, Inc. is pleased to announce the filing of a U.S. patent application concerning methods and formulations to achieve targeted tumor cell death. MCT-485 is a noncoding double stranded micro RNA (miRNA) which has demonstrated oncolytic and immune stimulating activity in in vitro

read more>>

Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, announced a Phase 1/2 study of UX003 for mucopolysaccharidosis type 7 (MPS 7, or Sly Syndrome). UX003 is a recombinant human b-glucuronidase intended as an enzyme The

read more>>